Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
[Feature articles] “Cancer patient-derived non clinical model for drug development” Editor:Yoshikatsu Koga
Establishment and utilization of patient-derived xenograft (PDX) models for cancer pharmacological research
Masami Suzuki
Author information
JOURNAL FREE ACCESS

2024 Volume 39 Issue 3 Pages 201-209

Details
Abstract
A patient-derived xenograft (PDX) model was established by directly transplanting surgically resected human tumor tissue into immunodeficient mice without in vitro culture, followed by maintenance through in vivo passage. This model helped retain the histological structure, cell morphology, and molecular and genetic properties of human tumor tissues. As a model that reflects the diversity and complexity of tumors, it can be used in the research and development of molecularly targeted drugs. Although PDX models are valuable research tools, the development and utilization of established PDX lines require different research plans compared to those commonly used for in vitro cultured tumor cell lines. This section describes the characteristics of PDX models as tumor models and elucidates the points to consider when attempting to establish and use PDX models.
Content from these authors
© 2024 The Japan Society of Drug Delivery System
Previous article Next article
feedback
Top